Jeevan Scientific Technology Limited has announced the successful completion of the US FDA Remote Regulatory Assessment process and the issuance of the corresponding assessment report. The company informed the BSE through a regulatory filing dated January 22, 2026, marking a significant milestone in its regulatory compliance journey.

FDA Assessment Details

The US FDA conducted a comprehensive Remote Regulatory Assessment and Remote Record Review of the company's clinical pharmacology facility. The assessment covered studies conducted over a specific period and involved detailed scrutiny of the company's operations and compliance standards.

Regulatory Compliance Update

This announcement represents the conclusion of a regulatory process that began earlier in 2025. The company had previously disclosed the commencement of this FDA assessment on November 7, 2025, keeping stakeholders informed throughout the process.

The successful completion of the FDA assessment demonstrates the company's commitment to maintaining international regulatory standards. The Remote Regulatory Assessment Report serves as official documentation of the FDA's review findings regarding the company's clinical pharmacology operations.

Corporate Communication

The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring transparency with investors and regulatory authorities. Managing Director Krishna Kishore Kuchipudi signed the official communication, emphasizing the importance of this regulatory milestone for the organization.

The company's proactive approach to regulatory compliance and transparent communication with exchanges reflects its commitment to maintaining high operational standards in the pharmaceutical sector.

Jeevan Scientific Technology Limited has successfully completed its Rs 30.74 crore capital raising plan through the allotment of convertible warrants and equity shares. The company's board meeting held on January 2, 2026, approved the allotment of securities to promoters and non-promoters following BSE's in-principle approval.

Major Stake Acquisition by Padmaja Private Trust

In a significant development, Padmaja Private Trust has acquired a substantial 7.53% stake in the company through the recent preferential allotment. The acquisition details are as follows:

This acquisition triggered disclosure requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as Padmaja Private Trust crossed the substantial acquisition threshold.

SEBI Regulatory Compliance

Following the acquisition, Padmaja Private Trust has filed the mandatory disclosure under Regulation 29(1) of SEBI regulations on January 5, 2026. The filing confirms the acquisition details and provides comprehensive information about the trust's holdings:

Complete Allotment Details

The board has successfully allotted the planned securities as outlined in their earlier proposal:

The allotment was completed pursuant to BSE's in-principle approval granted through Letter Reference No. LOD/PREF/HC/FIP/1377/2025-26 dated December 18, 2025.

Updated Capital Structure

Following the allotment, the company's equity capital structure has been revised:

Fund Utilization and Strategic Plans

The funds raised will be utilized for:

This successful capital raise and the entry of Padmaja Private Trust as a substantial investor strengthens Jeevan Scientific Technology's financial position and provides the necessary resources for its planned expansion in the healthcare sector, including potential acquisitions and capacity enhancement initiatives.